𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Germline 657del5 mutation in the NBS1 gene in breast cancer patients

✍ Scribed by Bohdan Górski; Tadeusz Dębniak; Bartlomiej Masojć; Marek Mierzejewski; Krzysztof Mędrek; Cezary Cybulski; Anna Jakubowska; Grzegorz Kurzawski; Maria Chosia; Rodney Scott; Jan Lubiński


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
60 KB
Volume
106
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

In this report the proportion of consecutive and familial breast cancer cases harboring the 657del5 of exon 6 of the NBS1 gene was determined to assess whether it is associated with the increased risk of breast cancer development. The study consisted of 3 groups of patients: a series of consecutive 150 patients with histologically confirmed breast cancer, diagnosed under the age of 50 in the city of Szczecin; a series of 80 breast cancer patients with a family history of breast cancer in their first‐degree relatives; and a series of 530 consecutive individuals without the diagnosis of breast cancer selected at random by family doctors from the city of Szczecin. Molecular examination included allele‐specific PCR assay for the common Slavic NBS1 mutation (657del5), LOH analysis using denucleotide CA repeat microsatellite markers, haplotype analysis and sequencing. The NBS1 founder mutation was detected in 2 of 150 (1.3%) consecutive breast cancer cases diagnosed under the age of 50 years; in 3 of 80 familial breast cancer cases (3.7%); and in 3 of 530 individuals (0.6%) from the general population. Examination of tumor DNA from patients with the NBS1 mutation (groups A and B) revealed loss of heterozygosity (LOH) in all cases. Additional haplotype analysis revealed that allelic loss affects specifically wild‐type alleles. The majority of probands with breast cancer and the NBS1 mutation had a positive family history of breast cancer in their first‐degree relatives. It appears that the 657del5 mutation in exon 6 of the NBS1 gene is responsible for the occurrence of a small but significant proportion of familial breast cancer patients. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Germline mutations 657del5 of the NBS1 g
✍ Jan Steffen; Dorota Nowakowska; Anna Niwińska; Dorota Czapczak; Anna Kluska; Mag 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB

## Abstract Recent studies have demonstrated that heterozygous carriers of the __NBS1__ 657del5 mutation have an increased risk for familial and bilateral breast cancer, but similar studies in consecutive breast cancer patients were inconclusive. Here, in a study of 562 nonselected breast cancer pa

Increased risk of gastrointestinal lymph
✍ Jan Steffen; Galina Maneva; Lidia Popławska; Raymonda Varon; Olga Mioduszewska; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB

## Abstract The __NBS1__ gene mutation, 657del5, frequent in the Slavic populations of Central Europe, is found in most patients with Nijmegen breakage syndrome (NBS), a recessive autosomal disorder with a very high incidence of non‐Hodgkin lymphoma (NHL). We have previously described 2 heterozygou

NBS1 657del5 mutation may contribute onl
✍ Konstantin G. Buslov; Aglaya G. Iyevleva; Elena V. Chekmariova; Evgeny N. Suspit 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 102 KB

## Abstract The gene for Nijmegen chromosomal breakage syndrome (__NBS1__) plays a role in a variety of processes protecting chromosomal stability. Recently, it was suggested in a Polish case‐control study that the founder hypomorphic mutation in __NBS1__, 657del5, which occurs in approximately 0.5

Germline mutations in the BRCA1 and BRCA
✍ A. Esra Manguoǧlu; Güven Lüleci; Tayfun Özçelik; Taner Çolak; Hagit Schayek; Mus 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 2 views

In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w